Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary: Jagsonpal Pharmaceuticals Limited** Jagsonpal's largest financial exposure is regulatory compliance risk (10.0/10 score), driven by incomplete BRSR disclosure and uncertain Extended Producer Responsibility (EPR) applicability—non-compliance with SEBI BRSR mandates could trigger enforcement action or market suspension. The company faces ₹0–2 crore in estimated compliance remediation costs, though actual EPR liability remains unquantified due to unknown product category classification under pharmaceutical waste rules. Critical gap: despite ₹268.7 crore revenue, the company reports zero Scope 1 and 2 emissions data, indicating either material underreporting or inadequate measurement systems, which violates BRSR disclosure requirements and exposes it to regulatory scrutiny. Immediate priority is clarifying EPR obligations, establishing emission baselines, and filing complete BRSR disclosures to mitigate delisting risk under SEBI enforcement framework.
Source: Jagsonpal Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.